Country: সিঙ্গাপুর
ভাষা: ইংরেজি
সূত্র: HSA (Health Sciences Authority)
CETRIMIDE; LIGNOCAINE
N.K. LUCK (S) PTE LTD
D04AB
0.15 g/100 g
SPRAY
CETRIMIDE 0.15 g/100 g; LIGNOCAINE 15 g/100 g
BUCCAL
Pharmacy Only
SEPTODONT
ACTIVE
1992-09-25
XYLONOR, 150 MG / 1.5 MG PER G, OROMUCOSAL SPRAY, SOLUTION IDENTIFICATION OF THE PRODUCT Quantitative and qualitative composition LIDOCAINE ................................................................................ 150.00 mg CETRIMIDE ................................................................................. 1.5 mg EXCIPIENTS: _ saccharin (E954), spearmint flavour (mixture of mint and eucalyptus essential oils), _ _dipropylene glycol, ethanol (96 per cent) _ QS ad 1 g of solution for dental use One metered dose contains 10 mg of lidocaine. Description Oromucosal spray, solution – 36 g in an atomizer. Clear liquid, not more intensely coloured than slightly yellow with a characteristic odour of spearmint. PHARMACOLOGICAL PROPERTIES PHARMACODYNAMIC PROPERTIES Pharmacotherapeutic group: local anaesthetics / Lidocaine combinations ATC code: N01BB52. The medicinal product is an association of: • Lidocaine: a local amide anaesthetic. When applied to the oral mucous membrane, it provides surface anaesthesia by controlling painful stimulation occurring in or just beneath the mucosa. The local anaesthetic effect of lidocaine occurs via reversible blockade of nerve fiber impulse propagation. • Cetrimide: a quaternary ammonium disinfectant with antiseptic properties. This action occurs via protein denaturation, enzyme inactivation and membrane damage of bacteria. Lidocaine in combination with cetrimide has an onset of action of 2 to 5 minutes and 10 to 20 minutes as duration of action. PHARMACOKINETIC PROPERTIES _Lidocaine _ Absorption Results from published studies performed in patients using various topical lidocaine-based preparations applied to healthy oral mucosa show that measured serum lidocaine levels remain well below the toxic range. (< 5 μg/mL). The peak serum level of lidocaine is dose dependent and was found to be between 0.016 μg/mL and 0.35 μg/mL. Distribution Lidocaine is 60% to 80% protein-bound to alpha-1-acid glycoprotein. Biotransformation Lidocaine is principally metabolized in the সম্পূর্ণ নথি পড়ুন